Scarica l'app Stockscreener
8.22
2.37%
0.19
Arvinas Inc Borsa (ARVN) Ultime notizie
ARVN|Arvinas Inc|Price:8.220|Chg%:+0.190 - TradingKey
Arvinas Inc (ARVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arvinas, Inc. $ARVN is Rangeley Capital LLC's 8th Largest Position - MarketBeat
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Arvinas Inc (ARVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arvinas (NASDAQ:ARVN) Upgraded at Wall Street Zen - MarketBeat
TradingKey - TradingKey
Caxton Associates LLP Decreases Stake in Arvinas, Inc. $ARVN - MarketBeat
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Arvinas, Inc. Revenue Breakdown – NASDAQ:ARVN - TradingView
Arvinas Inc (ARVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arvinas (ARVN) AGM 2026 Summary - Quartr
Arvinas (ARVN) Proxy filing Summary - Quartr
Trading the Move, Not the Narrative: (ARVN) Edition - Stock Traders Daily
Arvinas (ARVN) Stock Forum and Discussion - Moomoo
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Protein Degrader Therapeutics (PROTACs & Molecular Glues) - openPR.com
Form 144 ARVINAS For: 9 July By Investing.com - Investing.com Nigeria
Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares - Stock Titan
ARVN Q1 2026 Earnings: EPS Beat Amidst No Revenue, Pipeline Progress in FocusGross Profit Margin - DonanımHaber
Why FDA approval for vepdegestrant is a major shift in cancer therapy - The Hindu
Arvinas Inc. (ARVN) Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Recognition Risk - dars.gov.et
ARVNArvinas Inc Latest SEC Filings - Finviz
Arvinas Inc. (ARVN) Narrows to a Fractional Decline, Stabilizing Near $8.29 Amid Low VolatilitySector Neutral Pair - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Form 4 Arvinas Inc For: 26 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4 - Stock Titan
Arvinas (ARVN) director receives RSU and stock option grants in equity award - Stock Titan
Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options - Stock Titan
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
Arvinas (ARVN) director receives new RSU and stock option awards - Stock Titan
Director Linda Bain receives RSUs and stock options at Arvinas (ARVN) - Stock Titan
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas, Inc. (NASDAQ: ARVN) Files Form 8-K: Key Company Details, Stock Info, and Compliance Disclosures (June 24, 2026) – Minichart - Minichart
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN) - TradingView
Arvinas Shareholders Back Directors, Pay and Auditor Choices - TipRanks
Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor - Stock Titan
ARVN Forecast — Price Target — Prediction for 2027 - TradingView
Arvinas CFO Andrew Saik sells $46,473 in company stock - Investing.com UK
Form 4 Arvinas Inc For: 24 June By Investing.com - Investing.com Nigeria
Arvinas CFO Andrew Saik sells $46,473 in company stock By Investing.com - Investing.com Australia
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):